Market Place
Sourcing Support
All News #Library
Biotech
Oncc4 Initiates Phase 1/2 Trial Of ONC-841 For Alzheimer
09 Apr 2026 //
PR NEWSWIRE
BioNTech & OncoC4 Show OS Benefit for Gotistobart in NSCLC
06 Dec 2025 //
GLOBENEWSWIRE
Oncc4 Secures $50M In Series B Funding For Advancing Candidate
02 Oct 2025 //
PR NEWSWIRE
OncoC4, BioNTech Co-Developing Gotistobart Monotherapy for NSCLC
08 Sep 2025 //
GLOBENEWSWIRE
OncoC4 Preclinical Data: ONC-841 May Treat Alzheimer’s
28 Jul 2025 //
GLOBENEWSWIRE
OncoC4 Begin Ph 2 of BIPAVE-001 Trial with AI-081 for Solid Tumor
22 Jul 2025 //
GLOBENEWSWIRE
OncoC4 and AcroImmune Announce Merger
25 Sep 2024 //
GLOBENEWSWIRE
OncoC4 Doses First Patient In ONC-841 Solid Tumor Trial
04 Sep 2024 //
GLOBENEWSWIRE
OncoC4 Gets FDA IND Clearance For SIGLEC10 Inhibitor ONC-841 In Solid Tumors
23 Apr 2024 //
GLOBENEWSWIRE
OncoC4 Announces First Patient Dosed in Ph 1/2 Trial of BNT316/ONC-392 Program
22 Feb 2024 //
GLOBENEWSWIRE
BioNTech and OncoC4 Present Positive Phase 1/2 Data for BNT316/ONC-392
02 Jun 2023 //
PRESS RELEASE
BioNTech signs deal to co-develop OncoC4`s cancer drug
21 Mar 2023 //
REUTERS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.